See more : Santen Pharmaceutical Co., Ltd. (SNPHY) Income Statement Analysis – Financial Results
Complete financial analysis of HilleVax, Inc. (HLVX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of HilleVax, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- C&C Group plc (CCGPY) Income Statement Analysis – Financial Results
- ULVAC, Inc. (6728.T) Income Statement Analysis – Financial Results
- Starhedge S.A. (SHG.WA) Income Statement Analysis – Financial Results
- Tekcapital plc (TEKCF) Income Statement Analysis – Financial Results
- ClearStream Energy Services Inc. (CSM.TO) Income Statement Analysis – Financial Results
HilleVax, Inc. (HLVX)
About HilleVax, Inc.
HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 2.16M | 2.25M | 3.00K | 0.00 | 0.00 |
| Gross Profit | -2.16M | -2.25M | -3.00K | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 106.68M | 45.91M | 10.01M | 0.00 | 0.00 |
| General & Administrative | 26.66M | 16.71M | 5.76M | 1.30M | 633.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 632.37K |
| SG&A | 26.66M | 16.71M | 5.76M | 1.30M | 633.00K |
| Other Expenses | 0.00 | -94.70M | -20.23M | -779.00K | 0.00 |
| Operating Expenses | 133.35M | 62.61M | 15.77M | 1.30M | 633.00K |
| Cost & Expenses | 133.35M | 62.61M | 15.77M | 1.30M | 633.00K |
| Interest Income | 9.71M | 3.88M | 2.84K | 29.00 | 9.00 |
| Interest Expense | 2.39M | 3.41M | 2.84M | 29.00K | 9.00K |
| Depreciation & Amortization | 879.00K | 2.25M | 3.00K | 1.30M | 633.00K |
| EBITDA | -132.47M | -65.11M | -99.56M | -2.07M | -31.00K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -133.35M | -65.11M | -53.43M | -1.30M | -633.00K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 9.78M | -94.70M | -48.98M | -808.00K | -40.00K |
| Income Before Tax | -123.57M | -159.81M | -102.41M | -2.10M | -673.00K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 97.20M | -17.38M | 29.00K | -633.00 |
| Net Income | -123.57M | -257.01M | -85.03M | -2.13M | -673.00K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -3.04 | -6.83 | -2.82 | -0.07 | -0.02 |
| EPS Diluted | -3.04 | -6.83 | -2.82 | -0.07 | -0.02 |
| Weighted Avg Shares Out | 40.60M | 37.66M | 30.19M | 30.19M | 30.19M |
| Weighted Avg Shares Out (Dil) | 40.60M | 37.66M | 30.19M | 30.19M | 30.19M |
What Makes HilleVax (HLVX) a New Buy Stock
HilleVax (HLVX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
HilleVax, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by HilleVax (HLVX)
NEW YORK, NY / ACCESSWIRE / August 29, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of HilleVax, Inc. ("HilleVax") (NASDAQ:HLVX) concerning possible violations of federal securities laws. On July 8, 2024, HilleVax was the...
Levi & Korsinsky Investigates Possible Securities Fraud Violations by HilleVax, Inc. (HLVX)
NEW YORK, NY / ACCESSWIRE / August 28, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of HilleVax, Inc. ("HilleVax") (NASDAQ:HLVX) concerning possible violations of federal securities laws. On July 8, 2024, HilleVax was the...
Investors who lost money on HilleVax, Inc. should contact Levi & Korsinsky about an ongoing investigation - HLVX
NEW YORK, NY / ACCESSWIRE / August 27, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of HilleVax, Inc. ("HilleVax") (NASDAQ:HLVX) concerning possible violations of federal securities laws. On July 8, 2024, HilleVax was the...
HilleVax, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - HLVX
NEW YORK, NY / ACCESSWIRE / August 26, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of HilleVax, Inc. ("HilleVax") (NASDAQ:HLVX) concerning possible violations of federal securities laws. On July 8, 2024, HilleVax was the...
ATTENTION HLVX SHAREHOLDERS: Investors who Lost Money on HilleVax, Inc. are Urged to Contact Levi & Korsinsky About an Ongoing Investigation
NEW YORK, NY / ACCESSWIRE / August 23, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of HilleVax, Inc. ("HilleVax") (NASDAQ:HLVX) concerning possible violations of federal securities laws. On July 8, 2024, HilleVax was the...
ATTENTION HLVX SHAREHOLDERS: Investors who Lost Money on HilleVax, Inc. are Urged to Contact Levi & Korsinsky About an Ongoing Investigation
NEW YORK, NY / ACCESSWIRE / August 22, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of HilleVax, Inc. ("HilleVax") (NASDAQ:HLVX) concerning possible violations of federal securities laws. On July 8, 2024, HilleVax was the...
HLVX ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your HilleVax, Inc. investment
NEW YORK, NY / ACCESSWIRE / August 20, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of HilleVax, Inc. ("HilleVax") (NASDAQ:HLVX) concerning possible violations of federal securities laws. On July 8, 2024, HilleVax was the...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of HilleVax, Inc. - HLVX
NEW YORK, NY / ACCESSWIRE / August 11, 2024 / Pomerantz LLP is investigating claims on behalf of investors of HilleVax, Inc. ("HilleVax" or the "Company") (NASDAQ:HLVX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of HilleVax, Inc. - HLVX
NEW YORK , Aug. 9, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of HilleVax, Inc. ("HilleVax" or the "Company") (NASDAQ: HLVX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Source: https://incomestatements.info
Category: Stock Reports